Therapeutic targets: progress of their exploration and investigation of their characteristics
- PMID: 16714488
- DOI: 10.1124/pr.58.2.4
Therapeutic targets: progress of their exploration and investigation of their characteristics
Abstract
Modern drug discovery is primarily based on the search and subsequent testing of drug candidates acting on a preselected therapeutic target. Progress in genomics, protein structure, proteomics, and disease mechanisms has led to a growing interest in and effort for finding new targets and more effective exploration of existing targets. The number of reported targets of marketed and investigational drugs has significantly increased in the past 8 years. There are 1535 targets collected in the therapeutic target database compared with approximately 500 targets reported in a 1996 review. Knowledge of these targets is helpful for molecular dissection of the mechanism of action of drugs and for predicting features that guide new drug design and the search for new targets. This article summarizes the progress of target exploration and investigates the characteristics of the currently explored targets to analyze their sequence, structure, family representation, pathway association, tissue distribution, and genome location features for finding clues useful for searching for new targets. Possible "rules" to guide the search for druggable proteins and the feasibility of using a statistical learning method for predicting druggable proteins directly from their sequences are discussed.
Similar articles
-
Matrix metalloproteinase inhibitors and cancer: trials and tribulations.Science. 2002 Mar 29;295(5564):2387-92. doi: 10.1126/science.1067100. Science. 2002. PMID: 11923519 Review.
-
Progress in the development of matrix metalloproteinase inhibitors.Curr Med Chem. 2008;15(14):1388-95. doi: 10.2174/092986708784567680. Curr Med Chem. 2008. PMID: 18537616 Review.
-
Proteomic validation of protease drug targets: pharmacoproteomics of matrix metalloproteinase inhibitor drugs using isotope-coded affinity tag labelling and tandem mass spectrometry.Curr Pharm Des. 2007;13(3):263-70. doi: 10.2174/138161207779313524. Curr Pharm Des. 2007. PMID: 17313360 Review.
-
Progress and problems in the exploration of therapeutic targets.Drug Discov Today. 2006 May;11(9-10):412-20. doi: 10.1016/j.drudis.2006.03.012. Drug Discov Today. 2006. PMID: 16635803 Review.
-
Intra- and interdomain flexibility in matrix metalloproteinases: functional aspects and drug design.Curr Pharm Des. 2009;15(31):3592-605. doi: 10.2174/138161209789271852. Curr Pharm Des. 2009. PMID: 19925414 Review.
Cited by
-
Identification of the key target profiles underlying the drugs of narrow therapeutic index for treating cancer and cardiovascular disease.Comput Struct Biotechnol J. 2021 Apr 21;19:2318-2328. doi: 10.1016/j.csbj.2021.04.035. eCollection 2021. Comput Struct Biotechnol J. 2021. PMID: 33995923 Free PMC article.
-
DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome.Nucleic Acids Res. 2011 Jul;39(Web Server issue):W492-8. doi: 10.1093/nar/gkr299. Epub 2011 May 10. Nucleic Acids Res. 2011. PMID: 21558322 Free PMC article.
-
Searching the Tritryp genomes for drug targets.Adv Exp Med Biol. 2008;625:133-40. doi: 10.1007/978-0-387-77570-8_11. Adv Exp Med Biol. 2008. PMID: 18365664 Free PMC article. Review.
-
An omics perspective on drug target discovery platforms.Brief Bioinform. 2020 Dec 1;21(6):1937-1953. doi: 10.1093/bib/bbz122. Brief Bioinform. 2020. PMID: 31774113 Free PMC article.
-
Large-scale identification of adverse drug reaction-related proteins through a random walk model.Sci Rep. 2016 Nov 2;6:36325. doi: 10.1038/srep36325. Sci Rep. 2016. PMID: 27805066 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous